Want to see AU:ATX full AI Analyst Report?
ATX Stock Chart & Stats
AU$0.14
-AU$0.01(-7.14%)
At close: 4:00 PM EDT
AU$0.14
-AU$0.01(-7.14%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.28
Previous CloseN/A
Volume422.49K
Average Volume (3M)555.23K
Market Cap
AU$56.46M
Enterprise ValueAU$93.06M
Total Cash (Recent Filing)AU$27.85M
Total Debt (Recent Filing)AU$341.11K
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding513,312,000
10 Day Avg. Volume286,186
30 Day Avg. Volume555,232
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-12.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.42Price Target Upside200.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Equity CushionA large equity base relative to assets provides a meaningful financial cushion and reduces balance-sheet fragility. Low leverage also preserves flexibility to fund clinical development and manage operating volatility without the same debt burden faced by highly leveraged companies.
Historically Strong Gross MarginsHigh gross margins in periods when revenue was generated indicate that the underlying offering has previously converted sales into substantial gross profit. If revenue is restored, this margin profile could support operating leverage, although current zero revenue means the benefit is not presently realized.
Cash Losses Track Net LossesCash losses broadly tracking reported net losses suggests the company is not experiencing a major additional cash drain beyond its accounting losses. This improves the quality of loss assessment and makes future progress in reducing reported losses more likely to translate into better cash generation.
Bears Say
Revenue Collapsed To ZeroThe disappearance of revenue removes current commercial support for the business and leaves development activities dependent on external funding or future product success. A zero-revenue base also makes the path to operating leverage and sustainable self-funded growth substantially longer.
Persistent And Widening LossesRecurring operating and net losses show that the company has not yet converted its activities into a profitable business model. Worsening losses increase the amount of future revenue or cost improvement required to reach breakeven and may constrain strategic choices over the next several quarters.
Increasing Cash BurnHigher operating cash burn reduces the time available to achieve clinical or commercial milestones before additional financing may be needed. Continued negative operating and free cash flow also limits internally funded investment and makes disciplined spending increasingly important.
Amplia Therapeutics News
ATX FAQ
What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest share price was AU$0.10 and its highest was AU$0.28 in the past 12 months.
What is Amplia Therapeutics Ltd.’s market cap?
Amplia Therapeutics Ltd.’s market cap is AU$56.46M.
When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
Amplia Therapeutics Ltd.’s upcoming earnings report date is Nov 25, 2026 which is in 49 days.
How were Amplia Therapeutics Ltd.’s earnings last quarter?
Amplia Therapeutics Ltd. released its earnings results on May 29, 2026. The company reported -AU$0.007 earnings per share for the quarter.
Is Amplia Therapeutics Ltd. overvalued?
According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Undervalued.
Does Amplia Therapeutics Ltd. pay dividends?
Amplia Therapeutics Ltd. does not currently pay dividends.
What is Amplia Therapeutics Ltd.’s EPS estimate?
Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amplia Therapeutics Ltd. have?
Amplia Therapeutics Ltd. has 513,312,000 shares outstanding.
What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
Amplia Therapeutics Ltd. reported an EPS of -AU$0.007 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amplia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.42 (200.00% Upside)
AU$0.42 (200.00% Upside)
Blogger Sentiment
Bullish
AU:ATX Sentiment 96%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
98.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Amplia Therapeutics Ltd.
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
ATX Stock 12 Month Forecast
Average Price Target
AU$0.42
▲(200.00% Upside)
Technical Analysis
Tryptamine Therapeutics
―
Neuren Pharmaceuticals Limited
―
Paradigm Biopharmaceuticals
―
Alterity Therapeutics
―
Zelira Therapeutics
―